Vir Biotechnology, Inc.
VIR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.17 | -0.12 | 0.05 |
| FCF Yield | -21.16% | -17.59% | -8.95% | -8.97% |
| EV / EBITDA | -4.52 | -5.09 | -5.26 | -8.77 |
| Quality | ||||
| ROIC | -18.20% | -10.80% | -11.84% | -9.10% |
| Gross Margin | -63,005.00% | -7,932.95% | -3,779.12% | -617.54% |
| Cash Conversion Ratio | 1.03 | 1.08 | 0.65 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | -47.84% | -66.17% | -63.98% | -64.19% |
| Free Cash Flow Growth | -36.76% | -53.94% | 11.44% | 48.20% |
| Safety | ||||
| Net Debt / EBITDA | 0.44 | 0.94 | 1.31 | 1.25 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -4.07 | -11.29 | -2.85 | 31.94 |